查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1195707

血管成形术球囊市场 - 增长、趋势、COVID-19 影响和预测 (2023-2028)

Angioplasty Balloons Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 120 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

血管成形术球囊市场预计将在 2021 年达到约 26.3925 亿美元，在 2027 年达到 33.4312 亿美元，预测期内（2022-2027 年）的复合年增长率约为 3.5%。

2020 年初爆发的 COVID-19，加上对合併症患者的严重影响，由于封锁规定，预计将对研究市场产生重大影响。 由于大流行，心臟治疗的延迟和取消影响了市场。 例如，2020 年 11 月发表的一项题为“COVID-19 大流行对 STEMI 患者机械再灌注的影响”的研究发现，直接经皮冠状动脉介入治疗 (PPCI) 手术减少了 19%，尤其是在高血压患者中。 COVID-19 大流行也对 ST 段抬高型心肌梗死 (STEMI) 患者的治疗产生了重大影响。 然而，根据约翰霍普金斯医学院 2022 年 4 月发表的一篇论文《COVID-19 之后的心臟问题》，冠状病毒可以直接感染和伤害心臟的肌肉组织，也可以损伤静脉和动脉。心臟内表面可能会感染冠状病毒，导致血栓、血管损伤、周围血管发炎，以及流向心臟和其他器官的血流受损。 因此，预计 COVID-19 将对心血管系统产生非常大的影响，这可能会在预测期内影响市场。

随着心血管疾病负担的增加和对微创手术的偏好，血管成形术球囊正在成为冠状动脉和外周动脉疾病患者的首选治疗方法。 心血管疾病在世界范围内以惊人的速度增长，需要具有高成功率的精确疗法。 例如，根据欧洲心臟网2021年公布的数据，欧盟有超过6000万人患有心血管疾病，每年新增确诊病例近1300万。 预计上述因素将在预测期内推动市场增长。

生活方式疾病患病率上升和老年人口增加等因素正在推动血管成形术球囊市场的增长。 例如，根据世界卫生组织 (WHO) 2021 年 10 月更新，估计 60 岁及以上人口将从 2020 年的 10 亿增加到 21 亿。 因此，随着老年人口的增加，慢性病，尤其是心血管疾病的患病率预计也会增加，从而导致住院和手术。 此外，市场参与者越来越多地推出创新产品以满足不断增长的需求也有望推动市场增长。 例如，2021年3月，美敦力在欧洲安妮地区推出了用于经皮腔内血管成形术的“变色龙”球囊导管。 然而，与血管成形术相关的高成本和术后并发症预计会阻碍市场增长。

血管成形术球囊的市场趋势

预计在预测期内，医院部分将主导血管成形术球囊市场

预计医院部分将占整个血管成形术球囊市场的主要份额。 该细分市场的主导因素是先进的医疗基础设施、熟练劳动力的增加和负担能力。 此外，患有动脉硬化和心力衰竭等生活方式相关疾病的老年人口显着增加，预计将增加患者数量并提高医院利润。

此外，微创手术与传统手术相比的几个优点是微创球囊血管成形术，如减少手术疼痛、损伤、疤痕、住院、准确率高、恢復时间快等。鼓励许多患者选择 根据美国心脏病学会 2020 年报告的数据，美国每年大约进行 120 万例血管成形术手术。 此外，与专科诊所相比，医院的便利性和可负担性预计将吸引更多患者。

但是，由于当前 COVID-19 的情况，目前医院居民的行动受到限制。 除了紧急情况，人们希望避免手术或诊断程序以降低感染 COVID-19 的风险。 医院还将工作人员从心臟部门转移到其他需要的部门，例如 ED 和重症监护病房 (ICU)。 预计所有这些因素都会影响市场的增长。 然而，这种增长放缓是暂时的，从长远来看，市场有望显着增长。

下图显示，由于生活方式的改变和肥胖的增加，心血管疾病负担在北美等发达地区持续增加。 预计此类疾病的激增将推动血管成形术球囊市场的需求。

预计在预测期内北美将占据血管成形术球囊市场的重要份额

北美占血管成形术球囊市场的最大收入份额。 主要行业参与者的存在、医疗保健支出的增加、经皮冠状动脉介入治疗的增加等是该地区市场的主要驱动力。 根据疾病控制和预防中心 (CDC) 的数据，到 2022 年，美国每年将有大约 659,000 人死于心脏病，占死亡人数的四分之一。 因此，对先进医疗设备作为推动研究市场的主要因素的更好治疗存在很高的需求。

美国监管机构对产品批准的增加预计也将推动市场增长。 2020年11月，InfinityAngioplasty Balloon Co.推出了名为Infinity Angioplasty Balloon Catheter的革命性血管成形术球囊平台，并完成了首次人体临床试验。 该设备于 2020 年 6 月获得美国食品和药物管理局批准，用于治疗外周动脉疾病的 PTA，包括髂动脉、股动脉、腘动脉和膝下动脉，以及动静脉透析瘘的治疗。 这些新兴市场的发展有望进一步增强这些市场的产品阵容，并为该地区的市场提供有利可图的增长机会。

血管成形术球囊市场竞争对手分析

血管成形术球囊市场是分散的，有许多知名企业。 从市场份额的角度来看，目前几家大型企业占据了市场主导地位。 目前主导市场的公司包括 Abbott laboratories、Angiodynamic、Becton Dickinson、Biotronik、Boston Scientific Corporation、Braun Melsungen AG、Cook Medical、Cordis、Endocor GmbH、Infinity Angioblast balloon、Johnson & Johnson、Koninklijke Philips N.V.、Medtronic plc.、Merit Medical System, Inc、Oscor Inc、Terumo Corporation 等等。

其他好处

  • Excel 格式的市场预测 (ME) 表
  • 3 个月的分析师支持

内容

第1章介绍

  • 研究假设和市场定义
  • 调查范围

第2章研究方法论

第 3 章执行摘要

第4章市场动态

  • 市场概览
  • 市场驱动力
    • 增加心血管疾病的负担
    • 对微创手术和技术进步的偏好上升
  • 市场製约因素
    • 与手术相关的高成本
    • 与血管成形术相关的并发症
  • 波特的五力分析
    • 新进入者的威胁
    • 买方/消费者议价能力
    • 供应商的议价能力
    • 替代品的威胁
    • 竞争公司之间的敌对关係

第 5 章市场细分

  • 按产品类型
    • 普通气球
    • 切割/刻划气球
    • 药物洗脱球囊
  • 通过申请
    • 冠状动脉成形术
    • 外周血管成形术
  • 最终用户
    • 医院
    • 门诊手术中心
    • 其他最终用户
  • 按地区
    • 北美
      • 美国
      • 加拿大
      • 墨西哥
    • 欧洲
      • 德国
      • 英国
      • 法国
      • 意大利
      • 西班牙
      • 其他欧洲地区
    • 亚太地区
      • 中国
      • 日本
      • 印度
      • 澳大利亚
      • 韩国
      • 其他亚太地区
    • 中东
      • 海湾合作委员会
      • 南非
      • 其他中东地区
    • 南美洲地区
      • 巴西
      • 阿根廷
      • 其他南美洲

第6章竞争格局

  • 公司简介
    • Abbott Laboratories
    • AngioDynamics
    • Becton Dickinson
    • BIOTRONIK
    • Boston Scientific Corporation
    • Braun Melsungen AG
    • Cook Medical
    • Cordis（Cardinal Health）
    • Endocor GmbH
    • INFINITY Angioplasty Balloon
    • Johnson & Johnson
    • Koninklijke Philips N.V.
    • Medtronic Plc
    • Merit Medical Systems, Inc.
    • Oscor Inc.
    • Terumo Corporation

第7章 市场机会与今后动向

简介目录
Product Code: 64158

The angioplasty balloons market was valued at about USD 2639.25 million in 2021 and is expected to reach USD 3343.12 million in 2027, registering a CAGR of nearly 3.5% during the forecast period (2022-2027).

The emergence of COVID-19 in early 2020 was expected to have a significant impact on the studied market owing to the lockdown restrictions coupled with the severe impact of COVID-19 on people with comorbidities. Due to the pandemic, delay or cancellation in cardiology procedures was observed which affected the market. For instance, according to the research study published in November 2020, titled "Impact of COVID-19 Pandemic on Mechanical Reperfusion for Patients With STEMI", there was a 19% decrease in primary percutaneous coronary intervention (PPCI) procedures, particularly among patients with hypertension. Also, the COVID-19 pandemic had a significant impact on the care of patients with ST-segment elevation myocardial infarction (STEMI). However, according to an article published in April 2022 by John Hopkins Medicine, titled "Heart Problems after COVID-19", the coronavirus may directly infect and harm the heart's muscular tissue, and also, the inner surfaces of veins and arteries can become infected by the coronavirus, which can then lead to blood clots, blood vessel damage, and inflammation of surrounding blood vessels, all of which can impair blood flow to the heart and other organs. Hence, COVID-19 is expected to have a very significant impact on the cardiovascular systems which may affect the market over the forecast period.

With the increasing burden of cardiovascular diseases and the preference for minimally invasive surgery, balloon angioplasty has become the method of choice to treat patients suffering from coronary and peripheral artery diseases. Cardiovascular diseases worldwide are increasing at an enormous rate, which calls for precise treatment alternatives with high success rates. For instance, the data published by the European Heart network in 2021 reported that in the European Union, more than 60 million people live with cardiovascular disease, and nearly 13 million new cases of cardiovascular diseases are diagnosed yearly. The above-mentioned factors are expected to drive the growth of the market during the forecast period.

Factors such as the rising prevalence of lifestyle-related disorders and increasing geriatric populations are fueling the growth of the angioplasty balloons market. For instance, according to the World Health Organization (WHO) October 2021 update, the estimated population of people aged 60 years or more is expected to increase from 1 billion in 2020 to 2.1 billion. Thus, with an increase in the geriatric population, the prevalence of chronic diseases, especially cardiovascular disease, is also expected to increase, resulting in hospital admissions and surgeries. Additionally, the increasing innovative launches by market players to meet the growing demand are also expected to boost the growth of the market. For instance, in March 2021, Medtronic launched the chameleon percutaneous transluminal angioplasty balloon catheter in the Europeann regions. However, high costs and the post-operational complications associated with angioplasty are expected to hamper the market growth.

Angioplasty Balloons Market Trends

Hospitals Segment is Expected to Dominate the Angioplasty Balloons Market Over the Forecast Period

The hospital segment is expected to hold a major share of the overall angioplasty balloons market. The factors responsible for the dominance of this segment are advanced healthcare infrastructure, increasing availability of skilled labor, and affordability. In addition, the substantial growth in the geriatric population suffering from lifestyle diseases, such as atherosclerosis and heart failure, is expected to increase the patient pool and enhance hospital revenue generation.

Moreover, compared to conventional surgeries, the several advantages of minimally invasive surgeries, such as reduced surgical pain, injury, scarring, hospital stay, higher accuracy, and speedy recovery time, encourage more patients to opt for minimally invasive balloon angioplasty surgeries. As per the data reported by the American College of Cardiology in 2020, approximately 1.2 million angioplasties are performed in a year in the United States. Moreover, the high accessibility and affordability of hospitals, as compared to specialty clinics, are expected to attract a large patient population.

However, due to the current COVID-19 situation, limited movement of the population in hospitals is being observed. Except for an emergency, people are keen to avoid undergoing surgery or diagnostic procedures to limit the risk of COVID-19 infection. In addition, hospitals have also transferred their personnel availability from cardiac departments to other departments in need, such as EDs or intensive care units (ICU). All these factors are expected to affect the market growth. Nevertheless, this slowdown in growth is anticipated to be temporary, and in the long run, the market is expected to have significant growth.

The graph below suggests that the burden of cardiovascular disease is continuously surging in developed regions, such as North America, owing to the change in lifestyle habits and the high burden of obesity among the population. This surge in disease prevalence is expected to boost the demand for the angioplasty balloons market.

North America is Expected to Hold a Significant Share in the Angioplasty Balloons Market Over the Forecast Period

North America accounted for the maximum revenue share in the angioplasty balloons market. The presence of key industry players, the rising healthcare expenditure, and the growing number of percutaneous coronary interventions are the primary drivers of the market in the region. According to the Centers for Disease and Prevention (CDC), in 2022, about 659,000 people in the United States die from heart disease each year which is one in every four deaths. Thus, there exists a higher demand for better treatment with advanced medical devices, which acts as a major factor driving the studied market.

In addition, the increasing product approvals by regulatory bodies in the United States are also expected to drive the market's growth. In November 2020, InfinityAngioplasty Balloon Co. announced its innovative angioplasty balloon platform called Infinity Angioplasty Balloon Catheter and completed a First-in-Human clinical trial. The device received the Food and Drug Administration's clearance for PTA treatment of peripheral arterial disease in the peripheral vasculature, including iliac, femoral, popliteal, and infra-popliteal arteries, and for the treatment of arteriovenous dialysis fistulae in June 2020. All these developments are further expected to increase the robust product line of the market and are anticipated to offer lucrative growth opportunities to the market of this region.

Angioplasty Balloons Market Competitor Analysis

The angioplasty balloons market is fragmented, with many prominent players. In terms of market share, a few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are Abbott laboratories, Angiodynamic, Becton Dickinson, Biotronik, Boston Scientific Corporation, Braun Melsungen AG, Cook Medical, Cordis, Endocor GmbH, Infinity Angioblast balloon, Johnson & Johnson, Koninklijke Philips N.V., Medtronic plc, Merit Medical System, Inc, Oscor Inc, Terumo Corporation and others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Burden of Cardiovascular Diseases
    • 4.2.2 Increasing Preference for Minimally Invasive Procedures and Technological Advancements
  • 4.3 Market Restraints
    • 4.3.1 High Costs Associated with the Procedure
    • 4.3.2 Complications Associated with Angioplasty Procedures
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Product Type
    • 5.1.1 Normal Balloons
    • 5.1.2 Cutting/Scoring Balloons
    • 5.1.3 Drug Eluting Balloons
  • 5.2 By Application
    • 5.2.1 Coronary Angioplasty
    • 5.2.2 Peripheral Angioplasty
  • 5.3 By End User
    • 5.3.1 Hospitals
    • 5.3.2 Ambulatory Surgical Centers
    • 5.3.3 Other End Users
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle East
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Abbott Laboratories
    • 6.1.2 AngioDynamics
    • 6.1.3 Becton Dickinson
    • 6.1.4 BIOTRONIK
    • 6.1.5 Boston Scientific Corporation
    • 6.1.6 Braun Melsungen AG
    • 6.1.7 Cook Medical
    • 6.1.8 Cordis (Cardinal Health)
    • 6.1.9 Endocor GmbH
    • 6.1.10 INFINITY Angioplasty Balloon
    • 6.1.11 Johnson & Johnson
    • 6.1.12 Koninklijke Philips N.V.
    • 6.1.13 Medtronic Plc
    • 6.1.14 Merit Medical Systems, Inc.
    • 6.1.15 Oscor Inc.
    • 6.1.16 Terumo Corporation

7 MARKET OPPORTUNITIES AND FUTURE TRENDS